Engineered t cells take aim at Hard-to-Treat cancers in early trial
NCT ID NCT02989064
First seen Feb 04, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This early-stage study tested a new treatment for people with advanced bladder, skin (melanoma), or head and neck cancers. Doctors took patients' own immune cells, modified them in a lab to better recognize and attack cancer cells, and then infused them back. The main goal was to check safety and find the right dose, with 10 participants enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Hospital Universitario 12 Octubre Avda. de Córdoba
Madrid, 28041, Spain
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G1X6, Canada
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Start Madrid-FJD, Fundación Jimѐnez Díaz
Madrid, 28040, Spain
-
Tennessee Oncology - Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee, 37203, United States
-
Washington University - School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.